Gabapentin. CI 945, GOE 3450, Neurontin.
D000085:Acetates / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000328:Adult; D000588:Amines; D000927:Anticonvulsants / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D019540:Area Under Curve; D001682:Biological Availability; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D018592:Cross-Over Studies; D003509:Cyclohexanecarboxylic Acids; D004347:Drug Interactions; D000077206:Gabapentin; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy; D008881:Migraine Disorders / Q000188:drug therapy*; D010698:Phobic Disorders / Q000188:drug therapy; D005680:gamma-Aminobutyric Acid
D000085:Acetates; D000588:Amines; D000927:Anticonvulsants; D003509:Cyclohexanecarboxylic Acids; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin